Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

ELA026 showed favorable safety and achieved overall response rate (ORR) of 70% in sHLH patients Majority of enrolled patients were in difficult-to-treat subtypes of sHLH associated with malignancies and relapsed/refractory disease SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases […]

Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer

Company expands board of directors and appoints Matthew Fust as independent director Building on positive clinical results for its lead antibody candidate, Electra is positioned to expand therapeutic opportunities in immunological diseases and cancer SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets […]